130
Participants
Start Date
July 13, 2022
Primary Completion Date
July 11, 2025
Study Completion Date
July 11, 2025
e-liquid 1
30/70 PG/VG ratio with nicotine concentration 4mg/ml protonated
e-liquid 2
30/70 PG/VG ratio with nicotine concentration 10mg/ml protonated
e-liquid 3
30/70 PG/VG ratio with nicotine concentration 4mg/ml free base
e-liquid 4
30/70 PG/VG ratio with nicotine concentration 10mg/ml freebase
e-liquid 5
30/70 PG/VG ratio with nicotine concentration 0mg/ml (placebo)
e-liquid 6
30/70 PG/VG ratio with nicotine concentration 0mg/ml
e-liquid 7 and e-liquid 8
e-liquid 7: 30/70 PG/VG ratio with nicotine concentration 4mg/ml protonated e-liquid 8: 30/70 PG/VG ratio with nicotine concentration 8mg/ml protonated
e-liquid 9 and e-liquid 10
e-liquid 9: 30/70 PG/VG ratio with nicotine concentration 4mg/ml protonated e-liquid 10: 70/30 PG/VG ratio with nicotine concentration 4mg/ml protonated
American University of Beirut, Beirut
National Institutes of Health (NIH)
NIH
National Institute on Drug Abuse (NIDA)
NIH
American University of Beirut Medical Center
OTHER